LLY - Lilly-AbCellera collaboration develops new antibody that can neutralize COVID-19 variants

AbCellera ([[ABCL]] +0.8%) announced the preclinical data highlighting the efficacy of LY-CoV1404 a second antibody developed as part of its collaboration with Eli Lilly ([[LLY]] +1.2%).The new preclinical data have demonstrated that LY-CoV1404 can bind and neutralize ‘all currently known SARS-CoV-2 variants of concern,’ the company said.Neutralizing the original SARS-CoV-2 with high potency in vitro, LY-CoV1404 with the ability to bind to a rarely mutated region of the SARS-CoV-2 spike protein indicates its potential effectiveness against emerging COVID-19 variants, AbCellera added in the statement.LY-CoV1404 is developed from a fully human monoclonal antibody detected in a blood sample obtained nearly 60 days after the onset of symptoms in a convalescent COVID-19 patient.Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and in combination with other monoclonal antibodies.Bamlanivimab developed by AbCellera in partnership with Lilly was the first monoclonal antibody against COVID-19 to receive emergency use authorization from the FDA.

For further details see:

Lilly-AbCellera collaboration develops new antibody that can neutralize COVID-19 variants